UBS Group
BIVIW

UBS Group’s BioVie Inc Warrant BIVIW Stock Holding History

UBS Group’s Portfolio BIVIW Stock Details BIVIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-425
Closed -$115 – 11679
2025
Q4 		$115 Sell
425
-575
-58% -$188 ﹤0.01% 10169
2025
Q3 		$412 Buy
+1,000
New +$407 ﹤0.01% 9688

Other funds holding BIVIW

DC
Diametric Capital Boston, Massachusetts $385M AUM 31.69% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return
MA
MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return
HCM
Heights Capital Management San Francisco, California $359M AUM 7.93% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

UBS Group's BIVIW Position: Q1 2026 in Review

UBS Group sold out of BioVie Inc Warrant (BIVIW) in Q1 2026, closing a stake of 425 shares — an estimated $115 sold.

UBS Group first reported a position in BIVIW in Q3 2025 and held it in 2 quarters. The position peaked at $412 in Q3 2025. 8 funds tracked by Wall St. Rank hold BIVIW as of Q1 2026.

  • UBS Group reported no remaining BioVie Inc Warrant position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 425 BioVie Inc Warrant shares in Q1 2026, an estimated $115.
  • UBS Group first reported a position in BioVie Inc Warrant in Q3 2025 and held it in 2 quarters.
  • UBS Group's BioVie Inc Warrant position peaked at $412 in Q3 2025.
  • 8 funds tracked by Wall St. Rank held BioVie Inc Warrant as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.